Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

 
• By Anju Ghangurde

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

Hands holding rope forming arrow pointing upwards - Image
Momentum For Biocon-Mylan Biosimilars Portfolio • Source: Shutterstock

More from Business

More from Scrip